


11-28-05

[Handwritten signature]
\$



Express Mail Label No.: EV695511388US
Date of Deposit: November 22, 2005

Attorney Docket No.: 26505-513 (RIB-007)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Wang et al.
SERIAL NUMBER : 10/671,326 EXAMINER : Nyeemah Grazier
FILING DATE : September 25, 2003 ART UNIT : 1626
FOR : BIFUNCTIONAL HETEROCYCLIC COMPOUNDS AND METHODS
OF MAKING AND USING SAME

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited References: A42-A44; B59-B72; C19-C21;
4. Check in the amount of \$180.00 (#21536); and
5. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 26505-513 (RIB-007). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

[Handwritten signature]

Ivor R. Elrifi, Reg. No. 39,529
Heidi A. Erlacher, Reg. No. 45,409
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer No.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: November 22, 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Wang et al.
SERIAL NUMBER : 10/671,326 EXAMINER : Nyeemah Grazier
FILING DATE : September 25, 2003 ART UNIT : 1626
FOR : BIFUNCTIONAL HETEROCYCLIC COMPOUNDS AND METHODS
OF MAKING AND USING SAME

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Wang et al.
U.S.S.N.: 10/671,326

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 26505-513.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Heidi A. Erlacher, Reg. No. 45,409
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer no.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: November 22, 2005

TRA 2096133v.1



Express Mail No.: EV695511388US

Date of Deposit: November 22, 2005

Page 1 of 2

Attorney Docket No.: 26505-513 (RIB-007)

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/671,326		
				Filing Date	September 25, 2003		
				First Named Inventor	Wang		
				Group Art Unit	1626		
				Examiner Name	Nyeemah Grazier		
				Attorney Docket Number	26505-513 (RIB-007)		
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A42	5,658,888	08-19-97	Koga et al.	514	29	10-19-94
	A44	6,878,691 B2	04-12-05	Or et al.	514	29	05-05-03
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A43	2004/0157787 A1	08-12-04	Or et al.	514	28	11-19-03
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	B59	WO 99/64416	ZENECA LIMITED GB	12-16-99			
	B60	WO 99/64417	ZENECA LIMITED GB	12-16-99			
	B61	WO 00/40589	PLIVA, FARMACEUTSKA INDUSTRIJA. DIONICKO DRUSTVO	07-13-00			
	B62	WO 01/40236 A2	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	06-07-01			
	B63	WO 02/051855 A2	KOSAN BIOSCIENCES, INC	07-04-02			
	B64	WO 02/080841 A2	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10-17-02			
	B65	WO 02/081468 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10-17-02			
	B66	WO 02/081469 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10-17-02			
	B67	WO 02/096890 A2	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	12-05-02			
	B68	WO 02/096916 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	12-05-02			
	B69	WO 2004/013153 A2	ZAMBON GROUP S.P.A.	02-12-04			

Express Mail No.: EV695511388US
Date of Deposit: November 22, 2005

Page 2 of 2
Attorney Docket No.: 26505-513 (RIB-007)

	B70	WO	2004/048392 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	06-10-04		
	B71	WO	2004/056819 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	07-08-04		
	B72	EP	0643068 B1	CHUGAI SEIYAKU KABUSHIKI KAISHA TOKYO 115 JP	08-19-98		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C19	Jones, P.H., and Powley, E.K., "Chemical Modifications of Erythromycin Antibiotics. I. 3'-De(dimethylamino)erythromycin A and B," J. Org. Chem., 33:665-670 (1968).
	C20	Stenmark, Heather G., et al., "Biomimetic Synthesis of Macrolide/Ketolide Metabolites through a Selective N-Demethylation Reaction," J. Org. Chem., 65:3875-3876 (2000).
	C21	Liang, Chang-Hsing, et al., "Synthesis and Biological Activity of New 5-O-Sugar Modifies Ketolide and 2-Fluoro-Ketolide Antibiotics," Bioorganic & Medicinal Chem. Letters, 15:1307-1310 (2005).

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.